| Scope and Method of Study: This study examined the effects of freeze-dried mango (1% or 10% by weight), a fruit rich in vitamins A and C as well as phenolic compounds, in modulating clinical parameters of mice fed high fat (HF) diet. The study also compared the effects of mango to rosiglitazone (50 ppm), a glucose-lowering drug, and determined if addition of mango to a lower dose of rosiglitazone (25 ppm) will have similar effects. Two-month old male C57BL/6 mice were randomly assigned to one of the seven dietary treatment groups (n=8/group) for 60 days: AIN-control (10% fat calories), HF (60% fat calories), HF+1% or 10% mango, HF+50 ppm rosiglitazone, HF+1% mango or 10% mango+25 ppm rosiglitazone. An intraperitoneal glucose tolerance test was performed at 30 and 60 days of treatment. Mice were sacrificed and soft tissues as well as blood were collected after 60 days of treatment. Body composition, clinical parameters (serum HbA1c, plasma glucose, cholesterol, HDL-C, fructosamine, insulin, and triglycerides), and total lipids (i.e. liver and fecal) were determined. Histology was performed on liver and white adipose tissue.;Findings and Conclusions: As expected, body weight increased after the consumption of HF diet. Both doses of mango had similar effect on final body weight to the rosiglitazone group but also not statistically different from the HF group. Mango at 1% dose slightly improved body composition but also not statistically different from the HF group. Plasma free fatty acid was modulated by 1% mango but not quite to the level of rosiglitazone. There were no significant differences in plasma lipids and fructosamine among the HF-fed groups. The HF+50 ppm rosiglitazone group had the lowest glucose area under the curve after a glucose tolerance test. In brief, mango supplementation (1% or 10%) has modest effects on clinical parameters in mice fed high fat diet. Mango combined with a lower dose of rosiglitazone (25 ppm) was not as effective as the higher dose of rosiglitazone (50 ppm) in improving the assessed clinical parameters. Future study should use newly freeze-dried mango powder with known origin and maturity. Additionally, storage conditions should also be carefully controlled to determine the exact relationship between mango supplementation and its effects on clinical parameters. |
